- Home
- LSBK vs HLVX Comparison
LSBK vs HLVX Comparison
Compare LSBK & HLVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSBK
- HLVX
- Stock Information
- Founded
- LSBK 1891
- HLVX 2020
- Country
- LSBK United States
- HLVX United States
- Employees
- LSBK N/A
- HLVX N/A
- Industry
- LSBK Savings Institutions
- HLVX Biotechnology: Pharmaceutical Preparations
- Sector
- LSBK Finance
- HLVX Health Care
- Exchange
- LSBK Nasdaq
- HLVX Nasdaq
- Market Cap
- LSBK 76.9M
- HLVX 87.6M
- IPO Year
- LSBK 2006
- HLVX 2022
- Fundamental
- Price
- LSBK $13.51
- HLVX $1.83
- Analyst Decision
- LSBK
- HLVX Hold
- Analyst Count
- LSBK 0
- HLVX 5
- Target Price
- LSBK N/A
- HLVX $2.33
- AVG Volume (30 Days)
- LSBK 1.2K
- HLVX 130.0K
- Earning Date
- LSBK 10-23-2024
- HLVX 11-07-2024
- Dividend Yield
- LSBK 5.33%
- HLVX N/A
- EPS Growth
- LSBK N/A
- HLVX N/A
- EPS
- LSBK 0.75
- HLVX N/A
- Revenue
- LSBK $25,338,000.00
- HLVX N/A
- Revenue This Year
- LSBK N/A
- HLVX N/A
- Revenue Next Year
- LSBK N/A
- HLVX N/A
- P/E Ratio
- LSBK $18.10
- HLVX N/A
- Revenue Growth
- LSBK N/A
- HLVX N/A
- 52 Week Low
- LSBK $10.12
- HLVX $1.55
- 52 Week High
- LSBK $14.21
- HLVX $20.22
- Technical
- Relative Strength Index (RSI)
- LSBK 49.26
- HLVX 44.81
- Support Level
- LSBK $13.38
- HLVX $1.80
- Resistance Level
- LSBK $13.90
- HLVX $2.02
- Average True Range (ATR)
- LSBK 0.15
- HLVX 0.08
- MACD
- LSBK -0.02
- HLVX -0.00
- Stochastic Oscillator
- LSBK 37.14
- HLVX 13.95
About LSBK Lake Shore Bancorp Inc.
Lake Shore Bancorp Inc operates as a savings and loan holdings company. The bank's business consists of attracting retail deposits from the general public in the areas surrounding its branch offices and investing those deposits, together with funds generated from operations, in commercial real estate loans, one-to-four family residential mortgage loans, home equity lines of credit and, to a lesser extent, commercial business loans, consumer loans, and investment securities. Its revenues are principally derived from interest earned on loans and investment securities.
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.